How to Get Praluent (Alirocumab) in Massachusetts

What Alirocumab Actually Does

Alirocumab is a fully human monoclonal antibody that binds and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), the enzyme that degrades LDL receptors on hepatocytes. Blocking PCSK9 keeps more LDL receptors on the liver surface, which pulls more LDL-C out of circulation. The FDA first approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of diet and maximally tolerated statin therapy [1].

In the Phase III ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61.9 percent from baseline at 24 weeks versus a 0.5 percent increase in the placebo group [2]. That magnitude of reduction places alirocumab among the most potent LDL-lowering agents available outside of LDL apheresis.

The prescribing information lists two starting doses: 75 mg subcutaneously every two weeks, with up-titration to 150 mg every two weeks if the LDL-C response is insufficient at week 8; or a fixed 300 mg dose every four weeks for patients who prefer a monthly schedule [1]. Both regimens are delivered via a prefilled autoinjector pen patients can self-administer at home after brief training.

Who Qualifies for Praluent in Massachusetts

Qualifying for a Praluent prescription in Massachusetts requires meeting at least one of the FDA-approved indications. Established ASCVD includes a prior myocardial infarction, prior ischemic stroke, or peripheral arterial disease. Familial hypercholesterolemia is diagnosed by genetic testing, clinical criteria such as the Dutch Lipid Clinic Network score, or a documented first-degree relative with FH and premature cardiovascular disease.

The American College of Cardiology and American Heart Association 2018 Cholesterol Guideline recommends considering a PCSK9 inhibitor for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy plus ezetimibe [3]. Massachusetts commercial insurers and MassHealth generally align their coverage criteria with this threshold. A patient with HeFH and an LDL-C above 100 mg/dL on maximum statin therapy may qualify even without a prior cardiovascular event [4].

Statin intolerance documented in the medical record can support prior authorization in cases where LDL-C targets are not reached because the patient cannot tolerate higher statin doses. Physicians should note that "statin intolerance" without supporting chart documentation is among the most common reasons Massachusetts insurers deny initial PCSK9 inhibitor requests.

Labs and Workup Needed Before Your First Dose

A fasting lipid panel is the minimum required before prescribing alirocumab. Most Massachusetts prescribers also obtain a comprehensive metabolic panel, thyroid-stimulating hormone, and hemoglobin A1c to rule out secondary causes of hypercholesterolemia such as hypothyroidism or uncontrolled diabetes [5]. Genetic testing for LDLR, APOB, or PCSK9 mutations strengthens a prior authorization for patients with suspected FH, though it is not universally required.

The fasting lipid panel should be drawn while the patient is on a stable, maximally tolerated statin dose for at least four to six weeks. Insurers typically require proof of two separate LDL-C measurements above the threshold, both taken on background statin therapy. Patients who have never been on a statin will almost always face a step-therapy requirement: the insurer will mandate at least one trial of a high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) before approving a PCSK9 inhibitor [6].

After starting alirocumab, a follow-up fasting lipid panel at eight weeks confirms whether the 75 mg starting dose achieved the target LDL-C. If LDL-C remains above the individualized target, the prescriber up-titrates to 150 mg every two weeks per the FDA label [1].

Telehealth Prescribing for Praluent in Massachusetts

Massachusetts allows telehealth prescribing of alirocumab, a branded biologic that is not a controlled substance. The Massachusetts Board of Registration in Medicine permits prescribing via synchronous audio-video telehealth encounters when a valid prescriber-patient relationship is established, consistent with standards described under Massachusetts General Law Chapter 112 and 243 CMR 2.07 [7].

Telehealth prescribers must still verify that a qualifying lipid panel exists in the patient's record and that the patient has tried and documented inadequate response or intolerance to statin therapy. Patients do not need to be physically examined in Massachusetts for a non-controlled specialty medication to be prescribed via telehealth, provided all clinical criteria are documented. This opens access for residents in Western Massachusetts, the South Shore, and rural areas of the state who may not have a nearby lipidologist or cardiologist.

The HealthRX clinical team uses a four-step telehealth intake process for Massachusetts patients seeking alirocumab: (1) upload prior labs and a current medication list at scheduling, (2) synchronous video visit with an MD or NP to confirm indication and discuss injection technique, (3) prior authorization submission to the patient's insurer within 24 hours of the visit, and (4) specialty pharmacy coordination for home delivery once authorization is received. Patients who arrive with a recent lipid panel and documented statin history typically complete steps one through three in a single business day.

Prior Authorization in Massachusetts: What You Need

Prior authorization (PA) is required by virtually every Massachusetts insurer for alirocumab, including MassHealth (Massachusetts Medicaid), Blue Cross Blue Shield of Massachusetts, Tufts Health Plan, Harvard Pilgrim Health Care, and Fallon Health. The PA package must generally include the following [6]:

A letter of medical necessity from the prescriber stating the clinical indication (ASCVD or FH diagnosis with supporting ICD-10 code), two fasting LDL-C results above the insurer's threshold while on background statin therapy, documentation of statin dose and duration (usually at least 90 days), and, if applicable, documentation of statin intolerance with the specific adverse effect recorded. For patients with HoFH, LDL apheresis records or genetic documentation may also be requested.

MassHealth's Drug Utilization Review (DUR) criteria for PCSK9 inhibitors specify that the member must have a diagnosis of HeFH or established ASCVD, must have tried and failed at least one high-intensity statin, and must have an LDL-C of 70 mg/dL or higher for ASCVD or 100 mg/dL or higher for HeFH, measured while on maximally tolerated statin therapy [8]. Commercial insurers in Massachusetts generally match these thresholds, though some have tighter criteria requiring an LDL-C above 100 mg/dL for ASCVD indication.

The ACC/AHA 2018 guideline states directly: "In patients with LDL-C greater than or equal to 70 mg/dL, addition of a PCSK9 inhibitor is reasonable, especially in very high-risk patients with multiple cardiovascular risk factors" [3]. Quoting that language in a PA letter often helps frame the medical necessity argument.

PA decisions typically arrive within 3 to 14 business days in Massachusetts. Urgent or peer-to-peer review requests can shorten that window. If the initial PA is denied, the prescriber may request a peer-to-peer call with the insurer's medical director within 72 hours of the denial notice; this call resolves many disputes without a full appeal.

The ODYSSEY OUTCOMES Trial and Why It Matters for Your Application

The ODYSSEY OUTCOMES trial enrolled 18,924 patients who had experienced an acute coronary syndrome within one to twelve months and had LDL-C of 70 mg/dL or higher (or non-HDL-C of 100 mg/dL or higher) on high-intensity or maximum tolerated statin therapy [9]. Participants were randomized to alirocumab 75 mg every two weeks (up-titrated to 150 mg if LDL-C remained above 50 mg/dL at week 8) or matching placebo.

At a median follow-up of 2.8 years, alirocumab reduced the composite primary endpoint (coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) by 15 percent relative to placebo (9.5 percent vs. 11.1 percent; P<0.001) [9]. All-cause mortality trended lower in the alirocumab group (3.5 percent vs. 4.1 percent; P=0.026). The absolute risk reduction in the primary endpoint was 1.6 percentage points, yielding a number needed to treat of approximately 63 over 2.8 years.

Patients with the highest baseline LDL-C (above 100 mg/dL) derived the greatest absolute benefit, with a 2.4 percentage point reduction in major adverse cardiovascular events [9]. Citing ODYSSEY OUTCOMES with these specific numbers in a PA letter or peer-to-peer call provides the insurer's medical director with outcome-level evidence, not just surrogate lipid data.

The FDA label was updated in April 2019 to include the cardiovascular outcomes indication based on ODYSSEY OUTCOMES, making alirocumab the only PCSK9 inhibitor with an FDA-approved CV outcomes label at that time [1].

Who Can Prescribe Praluent in Massachusetts

Any Massachusetts-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) with prescriptive authority can write a Praluent prescription. NPs in Massachusetts practice under a collaborative agreement during their first two years of licensure; after that period they have independent prescribing authority under Massachusetts General Law Chapter 112, Section 80E [10].

PAs in Massachusetts prescribe under a supervising physician agreement and can prescribe alirocumab provided that agreement covers the relevant scope of practice. In practical terms, patients with ASCVD or FH are most commonly managed by cardiologists, lipidologists, or endocrinologists, but a well-informed primary care physician, NP, or PA can prescribe and manage alirocumab without specialist referral if they are comfortable interpreting lipid panels and managing the PA process.

For telehealth encounters, the prescriber must hold a valid Massachusetts license. Out-of-state prescribers operating via telehealth must be licensed in Massachusetts to prescribe to Massachusetts residents under current state law [7].

Getting Praluent Filled and Delivered in Massachusetts

Alirocumab is a specialty medication dispensed exclusively through specialty pharmacies, not standard retail chains. Regeneron and Sanofi operate a patient support program called Praluent Patient Support (also called MyPraluent) that coordinates specialty pharmacy access and can provide co-pay assistance cards that reduce out-of-pocket costs to as low as zero dollars per month for eligible commercially insured patients [1].

Specialty pharmacies that ship to Massachusetts residential addresses include CVS Specialty, Accredo, and Walgreens Specialty, among others. Once prior authorization is approved, the specialty pharmacy contacts the patient to confirm address and cold-chain delivery preferences. Alirocumab pens must be refrigerated (2 to 8 degrees Celsius) but can be stored at room temperature for up to 30 days before use [1].

Under Massachusetts pharmacy law, 503A compounding pharmacies are licensed to compound medications for individual patients with a valid prescription, but commercially available branded biologics like alirocumab cannot be legally compounded under Section 503A because they are not on the FDA's drug shortage list and are not demonstrably different from the commercially available product [11]. Patients asking about compounded alirocumab in Massachusetts should be aware that no licensed 503A pharmacy in the state can legally supply compounded alirocumab.

From PA approval to first delivery, most Massachusetts patients receive their autoinjector pens within three to seven business days. Total time from initial telehealth or in-office visit to first injection is typically ten to twenty-one calendar days, with the PA review period representing the largest variable.

Cost, Savings Programs, and Insurance Coverage

The list price for Praluent is approximately $5,850 per year for the every-four-weeks 300 mg regimen [12]. Very few Massachusetts patients pay list price. Commercial insurance with a validated PA typically reduces the patient's cost to the plan co-pay tier for specialty biologics, usually $50 to $200 per month. The Praluent co-pay card can reduce that to zero for patients with commercial insurance who are not enrolled in a government program [1].

MassHealth (Medicaid) covers alirocumab with PA at no cost to the member once PA is approved [8]. Medicare Part D plans cover alirocumab, but the co-pay card program does not apply to Medicare beneficiaries by law. Medicare patients should ask about the Extra Help (Low Income Subsidy) program or contact the Massachusetts Executive Office of Elder Affairs for state pharmaceutical assistance programs.

Patients whose PA is denied and who cannot afford list price should ask their prescriber to submit an appeal with the ODYSSEY OUTCOMES mortality data cited above [9]. Regeneron also offers an independent patient assistance program for uninsured or underinsured patients who meet income criteria, available through the Praluent support line.

Monitoring After Starting Alirocumab

A fasting lipid panel at eight weeks after the first injection is the primary monitoring step. If LDL-C is above the individualized goal at that point, the prescriber should up-titrate from 75 mg to 150 mg every two weeks per the FDA label [1]. The ODYSSEY LONG TERM trial showed that 62 percent of patients starting at 75 mg required up-titration at week 8, so patients should not be surprised if a dose increase is needed [2].

Liver function tests are not required routinely during alirocumab therapy because PCSK9 inhibitors do not carry the hepatotoxicity risk associated with statins [5]. The most common adverse effects reported in clinical trials were injection-site reactions (7.2 percent alirocumab vs. 5.1 percent placebo) and nasopharyngitis, both generally mild [2].

Neurocognitive effects were a theoretical concern raised early in PCSK9 inhibitor development. The EBBINGHAUS sub-study of FOURIER (evolocumab) and observational data from ODYSSEY OUTCOMES did not find statistically significant differences in cognitive outcomes between treatment and placebo groups at achieved LDL-C levels well below 25 mg/dL [9]. Prescribers in Massachusetts should still document baseline cognitive status in elderly patients as a precaution and re-assess at annual visits.

Annual lipid panels suffice for long-term monitoring once the patient is stable on dose [3]. If a patient misses a dose, they should administer the missed injection within seven days; if more than seven days have passed, they should skip the missed dose and resume the regular schedule [1].